US › Healthcare

MannKind Corp (MNKD)

US · Healthcare · Biotechnology

$3.96+4.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$90.2M
Revenue YoY
+15.1%
Net profit
$-16.6M
Profit YoY
-226.3%
EPS
$-0.02
EPS estimate
$0.01
Net margin
-18.4%

EPS came in at -0.02 against a street estimate of 0.01 — a miss of 398.5%.

Key statistics

Market cap
$1.21B
Forward P/E
41.3
P/B
187.85
Book value
$-0.19
EPS (TTM)
$-0.07
52-week high
$6.51
52-week low
$2.23
50-day MA
$3.86
200-day MA
$4.33
Beta
1.09

Analyst view

Analysts rate MannKind Corp a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $7.72.

Shareholding

Insiders
1.49%
Institutions
57.53%

Largest institutional holders

FundStake
BlackRock Inc9.26%
State Street Corp6.05%
Vanguard Capital Management, LLC4.17%
UBS Group AG2.67%
Geode Capital Management, LLC2.43%
Millennium Management LLC2.07%
Frazier Life Sciences Management, L.P.1.91%
Morgan Stanley - Brokerage Accounts1.88%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for MannKind Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.